CDKN2A is altered in 12.81% of oropharyngeal squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 5 clinical trials for oropharyngeal squamous cell carcinoma, of which 5 are open and 0 are closed. Of the trials that contain CDKN2A Expression and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [5].

CDKN2A is altered in 23.69% of head and neck squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A Expression and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

CDKN2A is altered in 30.77% of hypopharyngeal squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 2 clinical trials for hypopharyngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Expression and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

CDKN2A is altered in 40.0% of laryngeal squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 2 clinical trials for laryngeal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Expression and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

CDKN2A is altered in 17.81% of nasopharyngeal carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 2 clinical trials for nasopharyngeal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A Expression and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

CDKN2A is altered in 27.73% of oral cavity squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 2 clinical trials for oral cavity squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Expression and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [5].

CDKN2A is altered in 12.81% of oropharyngeal carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 2 clinical trials for oropharyngeal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A Expression and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

CDKN2A is altered in 4.15% of anal squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and anal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for high grade cervical intraepithelial neoplasia, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and high grade cervical intraepithelial neoplasia as inclusion criteria, 1 is early phase 1 (1 open) [5].

CDKN2A is altered in 1.56% of hodgkin lymphoma patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 11.23% of malignant solid tumor patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 11.85% of non-hodgkin lymphoma patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for oropharyngeal undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and oropharyngeal undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 27.18% of squamous cell carcinoma of unknown primary patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 25.93% of squamous cell carcinoma of the penis patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [5].

CDKN2A is altered in 27.08% of vulvar/vaginal squamous cell carcinoma patients [4].

CDKN2A Expression is an inclusion criterion in 1 clinical trial for vulvar/vaginal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A Expression and vulvar/vaginal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].